Glucagonoma differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(43 intermediate revisions by 6 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Glucagonoma}}
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Glucagonoma]]
{{CMG}}{{AE}}{{PSD}}
{{CMG}}; {{AE}} {{PSD}} {{MAD}}
 
==Overview==
==Overview==
Glucagonoma must be differentiated from certain skin lesions ([[acrodermatitis enteropathica]], [[psoriasis]], [[pellagra]], [[eczema]]) and other causes of hyperglucagonemia ([[infection]], [[diabetes mellitus]], [[Cushing syndrome]], [[renal failure]], [[acute pancreatitis]], severe stress, and prolonged fasting).
Glucagonoma must be differentiated from certain skin lesions in which [[necrolytic migratory erythema]] can be found such as [[acrodermatitis enteropathica]], [[psoriasis]], [[pellagra]], and [[eczema]]. Glucagonoma should be differentiated from other causes of [[hyperglycemia]] include [[infection]], [[diabetes mellitus]], [[Cushing syndrome]], [[renal failure]], [[acute pancreatitis]], severe stress, and prolonged fasting.


==Differentiating Glucagonoma from other Diseases==
==Differentiating Glucagonoma from other Diseases==
Glucagonoma must be differentiated from certain skin lesions in which necrolytic migratory erythema can be found and other causes of hyperglucagonemia:<ref>Glucagonoma. Wikipedia. https://en.wikipedia.org/wiki/Glucagonoma. accessed on October 10, 2015</ref><ref name="pmid25152626">{{cite journal| author=Fang S, Li S, Cai T| title=Glucagonoma syndrome: a case report with focus on skin disorders. | journal=Onco Targets Ther | year= 2014 | volume= 7 | issue=  | pages= 1449-53 | pmid=25152626 | doi=10.2147/OTT.S66285 | pmc=PMC4140234 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25152626  }} </ref>
Glucagonoma must be differentiated from certain [[skin lesions]] in which [[necrolytic migratory erythema]] can be found such as:<ref name="pmid25152626">{{cite journal| author=Fang S, Li S, Cai T| title=Glucagonoma syndrome: a case report with focus on skin disorders. | journal=Onco Targets Ther | year= 2014 | volume= 7 | issue=  | pages= 1449-53 | pmid=25152626 | doi=10.2147/OTT.S66285 | pmc=PMC4140234 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25152626  }} </ref>
* [[Pemphigus foliaceus]] 
* [[Pustular psoriasis]]
* [[Atopic dermatitis|Chronic eczema]]
* [[Acrodermatitis enteropathica]]
* [[Pellagra]]
 
{| class="wikitable"
{| class="wikitable"
! rowspan="2" |Disease
! rowspan="2" |Disease
Line 18: Line 23:
!Signs
!Signs
|-
|-
|Glucagonoma
|Glucagonoma<ref name="pmid4793623">{{cite journal |vauthors=Wilkinson DS |title=Necrolytic migratory erythema with carcinoma of the pancreas |journal=Trans St Johns Hosp Dermatol Soc |volume=59 |issue=2 |pages=244–50 |year=1973 |pmid=4793623 |doi= |url=}}</ref><ref name="pmid8606627">{{cite journal |vauthors=Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV |title=The glucagonoma syndrome. Clinical and pathologic features in 21 patients |journal=Medicine (Baltimore) |volume=75 |issue=2 |pages=53–63 |year=1996 |pmid=8606627 |doi= |url=}}</ref><ref name="pmid15313692">{{cite journal |vauthors=Zhang M, Xu X, Shen Y, Hu ZH, Wu LM, Zheng SS |title=Clinical experience in diagnosis and treatment of glucagonoma syndrome |journal=HBPD INT |volume=3 |issue=3 |pages=473–5 |year=2004 |pmid=15313692 |doi= |url=}}</ref><ref name="pmid17873310">{{cite journal |vauthors=Kindmark H, Sundin A, Granberg D, Dunder K, Skogseid B, Janson ET, Welin S, Oberg K, Eriksson B |title=Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years |journal=Med. Oncol. |volume=24 |issue=3 |pages=330–7 |year=2007 |pmid=17873310 |doi= |url=}}</ref>
|A family history of predisposing genetic disorders such as [[multiple endocrine neoplasia type 1]]
|A family history of [[multiple endocrine neoplasia type 1]]
|
|
* [[Necrolytic migratory erythema]] (NME) is a classical symptom observed in patients with glucagonoma and is present in 80% of cases. Associated NME is characterized by the spread of erythematous blisters and swelling across areas subject to greater friction and pressure, including the lower [[abdomen]], [[Buttock|buttocks]], [[perineum]], and [[groin]].<sup>[[Glucagonoma history and symptoms#cite note-pmid4793623-2|[2]]]</sup>
* [[Necrolytic migratory erythema]] characterized by the spread of erythematous blisters and swelling across areas subject to greater friction and pressure
* [[Weight loss]]<sup>[[Glucagonoma history and symptoms#cite note-pmid86066272-3|[3]]]</sup>
*Skin lesions involving the lower [[abdomen]], [[Buttock|buttocks]], [[perineum]], and [[groin]]
* [[Glucose intolerance]]<sup>[[Glucagonoma history and symptoms#cite note-pmid6268399-4|[4]]]</sup>
* [[Weight loss]]
* [[Glucose intolerance]]
|
|
* [[Rash|Rash:]] Erythematous, ring shaped [[rash]] that blisters, erodes, and crusts over suggesting [[necrolytic migratory erythema]].
* [[Rash|Rash:]] [[Erythematous]], ring shaped [[rash]] that blisters, erodes, and crusts over suggesting [[necrolytic migratory erythema]]
* Muscle [[atrophy]] may be present.
* Muscle [[atrophy]]
* Unilateral calf or thigh erythema, swelling, and erythema.
* Unilateral [[calf]] or [[thigh]] [[erythema]] and [[swelling]]
* Hyporeflexia may be present
* Hyporeflexia
* Unilateral/bilateral [[sensory loss]] in the upper/lower extremity may be present
* Unilateral/bilateral [[sensory loss]] in the upper/lower extremity  
|
|
* '''Serum glucagon'''<sup>[[Glucagonoma laboratory tests#cite note-pmid15313692-1|[1]]]</sup>
* '''Serum glucagon'''
** Normal [[Glucagon|glucagon level]] is less than 50 pg/mL.
** Increased plasma [[glucagon]] levels (>500 pg/mL)
** Increased plasma glucagon levels (>500 pg/mL).<sup>[[Glucagonoma laboratory tests#cite note-pmid8606627-3|[3]]]</sup>
** Concentrations above 1000 pg/mL are diagnostic of glucagonoma
** Concentrations above 1000 pg/mL are diagnostic of glucagonoma.<sup>[[Glucagonoma laboratory tests#cite note-pmid17873310-4|[4]]]</sup>


* CT scans are used to determine the location of the tumor, show the organs nearby, determining the stage of cancer and in determining whether surgery is a good treatment option.
* [[CT scan]] is used to determine:
* Sensitivity is >80 percent but it is decreased for tumors smaller than 2 cm.<sup>[[Glucagonoma CT#cite note-pmid21067742-2|[2]]]</sup>
**The location of the tumor
* Liver metastases may appear isodense with the liver on a non-contrasted study.<sup>[[Glucagonoma CT#cite note-pmid9574609-4|[4]]]</sup>
**Metastasis (usually liver metastasis)
|
***Appear isodense with the liver on a non-contrasted study
|[[File:NEM1.jpg|center|250px]]
|-
|-
|[[Liver cirrhosis|End-stage liver disease]]
|[[Pemphigus foliaceus]].<ref name="pmid15993235">{{cite journal| author=Bystryn JC, Rudolph JL| title=Pemphigus. | journal=Lancet | year= 2005 | volume= 366 | issue= 9479 | pages= 61-73 | pmid=15993235 | doi=10.1016/S0140-6736(05)66829-8 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15993235  }}</ref><sup>[[Pemphigus foliaceus#cite note-Bolognia-2|[2]]]</sup><ref name="pmid159414332">{{cite journal| author=Chams-Davatchi C, Valikhani M, Daneshpazhooh M, Esmaili N, Balighi K, Hallaji Z et al.| title=Pemphigus: analysis of 1209 cases. | journal=Int J Dermatol | year= 2005 | volume= 44 | issue= 6 | pages= 470-6 | pmid=15941433 | doi=10.1111/j.1365-4632.2004.02501.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15941433  }}</ref><ref name="pmid21353333">{{cite journal| author=Martin LK, Werth VP, Villaneuva EV, Murrell DF| title=A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. | journal=J Am Acad Dermatol | year= 2011 | volume= 64 | issue= 5 | pages= 903-8 | pmid=21353333 | doi=10.1016/j.jaad.2010.04.039 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21353333  }}</ref>
|[[Autoimmunity|Autoimmune]] blistering [[disease]] of the skin with characteristic lesions that are [[Scaly leg|scaly]], crusted erosions, often on an [[Erythematous rash|erythematous base]].<sup>[[Pemphigus foliaceus#cite note-Fitz2-1|[1]]]</sup>
 
[[Mucosal]] involvement is absent even with widespread [[disease]]
 
|
|
* Cutaneous lesion that usually develops in a [[Seborrheic eczema|seborrheic]] distribution
* The [[scalp]], [[face]], and [[trunk]] are common sites of involvement 
* [[Skin lesions]] may remain localized or may [[Coalescence (chemistry)|coalesce]] to cover large areas of [[skin]]
* Pain or burning sensations frequently accompany the cutaneous lesions
* Systemic symptoms are usually absent
|
|
|
* The skin lesions usually consist of small, scattered superficial [[blisters]]
|
** Lesions rapidly evolve into scaly, crusted erosions
|
** Positive [[Nikolsky's sign|Nikolsky sign]]
|-
|[[Pemphigus foliaceus]] 
|It is an autoimmune blistering disease of the skin with characteristic lesions that are scaly, crusted erosions, often on an erythematous base.<sup>[[Pemphigus foliaceus#cite note-Fitz2-1|[1]]]</sup>


Mucosal involvement is absent even with widespread disease.<sup>[[Pemphigus foliaceus#cite note-Bolognia-2|[2]]]</sup>


The pathway is most likely either of three mechanisms:
* Occasionally, [[pemphigus foliaceus]] progresses to involve the entire skin surface as an [[Exfoliative skin disease|exfoliative erythroderma]]
* Steric hindrance of the desmoglein 1: The antibody caps off the site for intracellular binding to another keratinocyte.
|Autoimmune [[IgG]] build up in the [[Epidermis (skin)|epidermis]], then nearly almost all of the [[antibodies]] are aimed against [[desmoglein 1]]
* Activation of an endocytic pathway: The antibody activates a pathway which causes an internalization of desmoglein 1, which in turn causes a loss of adhesion.
|[[File:Pemphigus foliaceus08.jpg|center|250px|thumb|<small>Courtesy:http://www.atlasdermatologico.com.br/index.jsf</small>]]
* Disruption of function: In this case, the antibody blocks the desmoglein 1 from being formed into a desmosome. This, in turn, causes a loss of adhesion with acantholysis as a result.
|
* Pemphigus foliaceus is a superficial variant of pemphigus that presents with cutaneous lesions.
* Pemphigus foliaceus usually develops in a seborrheic distribution.
<ref name="pmid15993235">{{cite journal| author=Bystryn JC, Rudolph JL| title=Pemphigus. | journal=Lancet | year= 2005 | volume= 366 | issue= 9479 | pages= 61-73 | pmid=15993235 | doi=10.1016/S0140-6736(05)66829-8 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15993235  }}</ref>
* The scalp, face, and trunk are common sites of involvement. The skin lesions usually consist of small, scattered superficial blisters that rapidly evolve into scaly, crusted erosions
* The skin lesions may remain localized or may coalesce to cover large areas of skin. Occasionally, pemphigus foliaceus progresses to involve the entire skin surface as an exfoliative erythroderma.<ref name="pmid159414332">{{cite journal| author=Chams-Davatchi C, Valikhani M, Daneshpazhooh M, Esmaili N, Balighi K, Hallaji Z et al.| title=Pemphigus: analysis of 1209 cases. | journal=Int J Dermatol | year= 2005 | volume= 44 | issue= 6 | pages= 470-6 | pmid=15941433 | doi=10.1111/j.1365-4632.2004.02501.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15941433  }}</ref>
* Pain or burning sensations frequently accompany the cutaneous lesions. Systemic symptoms are usually absent.
|Positive Nikolsky sign.<ref name="pmid21353333">{{cite journal| author=Martin LK, Werth VP, Villaneuva EV, Murrell DF| title=A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. | journal=J Am Acad Dermatol | year= 2011 | volume= 64 | issue= 5 | pages= 903-8 | pmid=21353333 | doi=10.1016/j.jaad.2010.04.039 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21353333  }}</ref>
|Autoimmune [[IgG]] build up in the [[Epidermis (skin)|epidermis]], then nearly almost all of the antibodies are aimed against [[desmoglein 1]]
|
|-
|-
|[[Psoriasis|Pustular psoriasis]]
|[[Psoriasis|Pustular psoriasis]]<sup>[[Psoriasis history and symptoms#cite note-pmid1390163-2|[2]]]</sup><sup>[[Psoriasis history and symptoms#cite note-pmid24790463-3|[3]]]</sup>
|
|
* Patients with early disease onset often have a positive family history of psoriasis, frequent association with [[histocompatibility]] [[antigen]] (HLA)- Cw6, and more severe disease. Those with onset after the age of 40 usually have a negative family history and a normal frequency of the HLA- Cw6 allele.<sup>[[Psoriasis history and symptoms#cite note-pmid1390163-2|[2]]]</sup>
* Positive family history of [[psoriasis]]
* A typical patient of psoriasis will present with a history of a long-term [[erythematous]] scaly area with [[ocular]] and [[joint]] involvement depending upon the clinical subtype and chronicity of the disease. There may be multiple relapses and remissions.
*Frequent association with [[histocompatibility]] [[antigen]] (HLA)- Cw6
* Past medical history of the patient may include [[viral]] or [[bacterial]] infection, [[Diabetes mellitus|diabetes]], [[hypertension]], [[chronic kidney disease]] and/or [[obesity]] due to an association of psoriasis with these conditions.<sup>[[Psoriasis history and symptoms#cite note-pmid24790463-3|[3]]]</sup>
* A history of a long-term [[erythematous]] scaly area with [[ocular]] and [[joint]] involvement
* Past medical history of the patient may include: 
**[[Viral]] or [[bacterial]] infection
** [[Diabetes mellitus|Diabetes]]
** [[Hypertension]]
** [[Chronic kidney disease]] 
**[[Obesity]]
|
|
* A long-term history of [[erythematous]] scaly area, which may involve multiple areas of the body    
* [[Pain]](unpleasant, superficial, sensitive, [[itchy]], hot or burning
* [[Pain]], which has been described by patients as unpleasant, superficial, sensitive, itchy, hot or burning (especially in erythrodermic psoriasis and in some cases of traumatized plaques or in the joints affected by psoriatic arthritis
* [[Pruritus]]
* [[Pruritus]] (especially in eruptive, guttate psoriasis)
* High [[fever]]
* High [[fever]]
* Dystrophic nails
* [[Dystrophic calcification|Dystrophic]] nails
* Long-term rash with recent presentation of [[arthralgia]]
* Recent presentation of [[arthralgia]]
|
|
* [[Papulosquamous disorder|Papulosquamous]] [[disease]] with variable morphology, distribution, severity, and course
* [[Papulosquamous disorder|Papulosquamous]] [[disease]] with variable morphology, distribution, severity, and course
* Scaling [[Papule|papules]] and [[Plaque|plaques]]
* Scaling [[Papule|papules]] and [[Plaque|plaques]]
* [[Koebner phenomenon]]: appearance of new psoriatic lesions at the site of skin injury
* [[Koebner phenomenon]]: appearance of new psoriatic lesions at the site of skin injury
* [[Woronoff|Woronoff’s ring]]: ring of peripheral blanching skin around a psoriatic [[plaque]]
* [[Woronoff|Woronoff’s ring]]: ring of peripheral blanching skin around a [[psoriatic]] [[plaque]]
* Auspitz’s sign: small [[bleeding]] points are seen upon disruption of a psoriatic scale.
* [[Auspitz's sign|Auspitz’s sign]]:
|'''Skin biopsy'''
** Small [[bleeding]] points are seen upon disruption of a [[psoriatic]] scale
 
|
Perivascular and [[dermal]] [[Inflammatory cells|inflammatory cell]] infiltration
* '''Skin biopsy'''
 
**Perivascular and [[dermal]] [[Inflammatory cells|inflammatory cell]] infiltration
[[Vascular]] dilation
**[[Vascular]] dilation
 
**Absent [[granular layer]]
Absent [[granular layer]]
**Elongation of [[dermal]] [[Papilla|papillae]]
 
**Parakeratosis
Elongation of [[dermal]] [[Papilla|papillae]]
**Spongiform [[pustules]] of Kogoj (pathognomic of psoriasis)
 
**Munro's micro abscesses (pathognomic of psoriasis)
Parakeratosis
**[[Edema]] of [[dermal]] [[papillae]]
 
**[[Basal cell layer]] is expanded
Spongiform [[pustules]] of Kogoj (pathognomic of psoriasis)
* [[Leukocytosis]]
 
|[[File:Pus.png|center|250px|thumb|<small>Courtesy:http://www.atlasdermatologico.com.br/index.jsf</small>]]
Munro's micro abscesses (pathognomic of psoriasis)
 
[[Edema]] of [[dermal]] [[papillae]]
 
In psoriasis, skin [[biopsy]] of the affected area of skin shows that the [[Epidermis (skin)|epidermal]]/supra-papillary thickness ratio is increased
 
[[Basal cell layer]] is expanded
 
Leukocytosis
|-
|-
|[[Acrodermatitis enteropathica]]
|[[Acrodermatitis enteropathica]]<ref name="pmid6696358">{{cite journal| author=Prasad AS, Cossack ZT| title=Zinc supplementation and growth in sickle cell disease. | journal=Ann Intern Med | year= 1984 | volume= 100 | issue= 3 | pages= 367-71 | pmid=6696358 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6696358  }}</ref><ref name="pmid1940572">{{cite journal| author=Meftah S, Prasad AS, Lee DY, Brewer GJ| title=Ecto 5' nucleotidase (5'NT) as a sensitive indicator of human zinc deficiency. | journal=J Lab Clin Med | year= 1991 | volume= 118 | issue= 4 | pages= 309-16 | pmid=1940572 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1940572  }}</ref><ref name="pmid9481631">{{cite journal| author=Kiliç I, Ozalp I, Coŝkun T, Tokatli A, Emre S, Saldamli I et al.| title=The effect of zinc-supplemented bread consumption on school children with asymptomatic zinc deficiency. | journal=J Pediatr Gastroenterol Nutr | year= 1998 | volume= 26 | issue= 2 | pages= 167-71 | pmid=9481631 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9481631  }}</ref>
|
|
* It is an [[autosomal]] [[recessive]] disorder characterized by periorificial and acral [[dermatitis]], [[alopecia]], and [[diarrhea]].
* An [[autosomal]] [[recessive]] disorder characterized by:
* The genetic base is a [[mutation]] of [[SLC39A4]] which encodes a [[transmembrane protein]] that serves as a zinc uptake protein
**Periorificial and acral [[dermatitis]], [[alopecia]], and [[diarrhea]]
* The genetic base is a [[mutation]] of [[SLC39A4]] which encodes a [[transmembrane protein]] that serves as a [[zinc]] uptake protein
|
|
* Symptoms appear in infants after breast milk weaning.
* Symptoms appear in infants after breast milk weaning
* The appearance of erythematous patches and plaques of dry, scaly skin.
* The appearance of erythematous patches and [[plaques]] of dry, [[Scal|scaly skin]]
* Diarrhea may occur.
* [[Diarrhea]]
|
|
* Erythematous patches and plaques of dry, scaly skin.
* [[Erythematous]]<nowiki/>patches/plaques of dry and [[Scale|scaly]] skin  


* The lesions may appear eczematous or may evolve further into crusted vesicles, bullae or pustules.
* The lesions may appear [[Eczematous Scaling|eczematous]] or may evolve into [[Crust|crusted]] [[vesicles]], [[Bulla|bullae]] or [[pustules]]
* The lesions are frequent around natural orifices like the mouth perioral and anus peri-anal, and also in hands, feet, and [[scalp]].
* The lesions are frequent in:
* There may be [[suppurative]] inflammation of the nail fold surrounding the nail plate - known as [[paronychia]]
**Mouth/ perioral
* Alopecia of the scalp, eyebrows, and eyelashes may occur. 
** [[Anus]]/ Peri-anal
**Also involves hands, feet, and [[scalp]]
* [[Paronychia]] 
* [[Alopecia]] of the scalp, eyebrows, and eyelashes 
|
|
* Measurement of zinc in plasma, erythrocytes, neutrophils, lymphocytes, and hair.
* Measurement of [[zinc]] in plasma, [[erythrocytes]], [[Neutrophil|neutrophils]], [[lymphocytes]], and hair


* A low plasma zinc usually is defined as a value less than 60 mcg/dL.
* A low plasma [[zinc]] usually is defined as a value less than 60 mcg/dL
* Zinc levels in neutrophils or lymphocytes may be more sensitive than plasma zinc.<ref name="pmid6696358">{{cite journal| author=Prasad AS, Cossack ZT| title=Zinc supplementation and growth in sickle cell disease. | journal=Ann Intern Med | year= 1984 | volume= 100 | issue= 3 | pages= 367-71 | pmid=6696358 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6696358  }}</ref>
* The criteria for [[zinc]] deficiency are decreased [[zinc]] level in [[lymphocyte]]
* The criteria for zinc deficiency are decreased zinc level in either lymphocyte.<ref name="pmid1940572">{{cite journal| author=Meftah S, Prasad AS, Lee DY, Brewer GJ| title=Ecto 5' nucleotidase (5'NT) as a sensitive indicator of human zinc deficiency. | journal=J Lab Clin Med | year= 1991 | volume= 118 | issue= 4 | pages= 309-16 | pmid=1940572 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1940572  }}</ref>
* Depressed serum [[alkaline phosphatase]] levels
* Depressed serum alkaline phosphatase levels for age provide supportive evidence for zinc deficiency.<ref name="pmid9481631">{{cite journal| author=Kiliç I, Ozalp I, Coŝkun T, Tokatli A, Emre S, Saldamli I et al.| title=The effect of zinc-supplemented bread consumption on school children with asymptomatic zinc deficiency. | journal=J Pediatr Gastroenterol Nutr | year= 1998 | volume= 26 | issue= 2 | pages= 167-71 | pmid=9481631 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9481631  }}</ref>
|[[File:Acrodermatitis enteropathica 05.png|center|250px|thumb|<small>Courtesy:http://www.atlasdermatologico.com.br/index.jsf</small>]]
|-
|-
|[[Pellagra]]
|[[Pellagra]]<ref name="pmid12777163">{{cite journal| author=Prousky JE| title=Pellagra may be a rare secondary complication of anorexia nervosa: a systematic review of the literature. | journal=Altern Med Rev | year= 2003 | volume= 8 | issue= 2 | pages= 180-5 | pmid=12777163 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12777163  }}</ref><ref name="pmid21128910">{{cite journal| author=Wan P, Moat S, Anstey A| title=Pellagra: a review with emphasis on photosensitivity. | journal=Br J Dermatol | year= 2011 | volume= 164 | issue= 6 | pages= 1188-200 | pmid=21128910 | doi=10.1111/j.1365-2133.2010.10163.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21128910  }}</ref>
|
|
* It is Niacin deficincy disease characterized by a photosensitive pigmented dermatitis (typically located in sun-exposed areas), diarrhea, and dementia.
* Niacin deficiency disease characterized by
* Hisotry of alcoholics, bariatric surgery, anorexia nervosa, or malabsorptive disease.<ref name="pmid12777163">{{cite journal| author=Prousky JE| title=Pellagra may be a rare secondary complication of anorexia nervosa: a systematic review of the literature. | journal=Altern Med Rev | year= 2003 | volume= 8 | issue= 2 | pages= 180-5 | pmid=12777163 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12777163  }}</ref>
**[[Photosensitivity|Photosensitivity]]
**Pigmented [[dermatitis]]
** [[Diarrhea]]
** [[Dementia]].
* Hisotry of:
**[[Alcoholic|Alcoholics]]
** [[Bariatric surgery]]
** [[Anorexia nervosa]]
** [[Malabsorption|Malabsorptive disease]]
* Dietary deficiency especially in infants
* Dietary deficiency especially in infants
* Past history of Carcinoid syndrome, in which metabolism of tryptophan is to 5-OH tryptophan and serotonin rather than to nicotinic acid. This leads to the deficiency of active forms of niacin and the development of pellagra.
* Past history of [[Carcinoid syndrome]]
* Prolonged use of isoniazid.<ref name="pmid21128910">{{cite journal| author=Wan P, Moat S, Anstey A| title=Pellagra: a review with emphasis on photosensitivity. | journal=Br J Dermatol | year= 2011 | volume= 164 | issue= 6 | pages= 1188-200 | pmid=21128910 | doi=10.1111/j.1365-2133.2010.10163.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21128910  }}</ref>
* Prolonged use of [[isoniazide]]
* A family history of Hartnup disease which is a congenital defect of a membrane transport in the intestinal and renal cells normally responsible for the absorption of tryptophan.
* A family history of [[Hartnup disease]]
|
|
* [[Photosensitivity]]
* [[Photosensitivity]]
* Pigmented dermatitis (typically located in [[sun-exposed areas]])
* [[Pigmented dermatitis]] in [[sun-exposed areas]]
* [[Diarrhea]]
* [[Diarrhea]]
* [[Dementia]]
* [[Dementia]]
* [[Glossitis]]
|Symmetric [[Hyperpigmentation|hyperpigmented]] [[rash]], similar in color and distribution to a sunburn, which is present in the exposed areas of skin
 
|[[Niacin]] status can be assessed by measuring urinary [[N-methylnicotinamide]] or by measuring the erythrocyte [[NAD|NAD/]][[NADP]] ratio 
* [[Insomnia]]
|[[File:Pellagra24.jpg|center|250px|thumb|<small>Courtesy:http://www.atlasdermatologico.com.br/index.jsf</small>]]
* [[Weakness|Weakness]]
* [[Mental confusion]]
|The most characteristic finding is the presence of a symmetric hyper pigmented rash, similar in color and distribution to a sunburn, which is present in the exposed areas of skin.
|Niacin status can be assessed by measuring urinary N-methylnicotinamide or by measuring the erythrocyte NAD/NADP (ratio). 
|-
|-
|[[eczema|Chronic eczema]] (atopic dermatitis)
|[[eczema|Chronic eczema]] ([[atopic dermatitis]])
|
|
* Atopic dermatitis is a chronic pruritic inflammatory skin disease that occurs most frequently in children but also affects adults.
* Chronic [[Pruritic disorders|pruritic]] inflammatory skin disease
* A family history of atopy (eczema, asthma, or allergic rhinitis) and the loss-of-function mutations in the filaggrin (''FLG'') gene, involved in the skin barrier function, are major risk factors for atopic dermatitis.
*Occurs most frequently in children but also affects adults
* History of dermatitis involving the skin creases.
* Family history of:
* Personal or family history of asthma or hay fever.
** [[Atopy]]
**([[Eczema]]
**[[Asthma]]
**[[Allergic rhinitis]])
* History of [[dermatitis]] involving the [[Skin crease|skin creases]]
* Personal or family history of [[asthma]] or [[hay fever]]
|
|
* Symptoms beginning in a child before the age of 2 years or, in children <4 years, dermatitis affecting the cheeks or dorsal aspect of extremities.
* Symptoms beginning in a child before the age of 2 years or, in children <4 years
* Dry skin and severe pruritus that is associated with cutaneous hyperreactivity to various environmental stimuli
* [[Dermatitis]] affecting the cheeks or dorsal aspect of extremities
* including exposure to food and inhalant allergens, irritants, and infection.
* Dry skin and severe [[pruritus]] that is associated with [[cutaneous]] [[hyperactivity]] to various environmental stimuli
* Exposure to:
**Food and inhalant allergens
**[[Irritants]]
**[[Infection]]
|
|
* Visible dermatitis involving flexural surfaces.
* Visible [[dermatitis]] involving flexural surfaces  
* Presence of generally dry skin within the past year
* Presence of generally dry skin within the past year
* Erythema, papulation, oozing and crusting, excoriation.
* [[Erythema]], [[papulation]], oozing and [[crusting]], [[excoriation]]
|
|
* Raised [[IgE]] or an [[eosinophilia]].
* Raised [[IgE]] or an [[eosinophilia]]
* [[RAST test|Radioallergosorbent Test]] Paper Radioimmunosorbent Test: in the test, blood is mixed separately with many different allergens and the antibody levels measured.
* [[RAST test|Radioallergosorbent Test]]:  
* High levels of antibodies in the blood signify an allergy to that substance.
**[[Blood]] is mixed separately with many different [[allergens]] and the [[antibody]] levels measured
* Skin biopsy which is a procedure that removes a small piece of the affected skin that is sent for microscopic examination in a pathology laboratory.
* [[Skin biopsy]]:
** A procedure that removes a small piece of the affected skin and sent for [[microscopic examination]] in a pathology laboratory
|[[File:Atopic Dermatitis27.jpg|center|250px|thumb|<small>Courtesy:http://www.atlasdermatologico.com.br/index.jsf</small>]]
|}
 
== Differentiating glucagonoma from other causes of hyperglycemia:==
Glucagonoma can be differentiated from other causes of hyperglycemia which include:<ref name="pmid17727381">{{cite journal| author=Barrett TG| title=Differential diagnosis of type 1 diabetes: which genetic syndromes need to be considered? | journal=Pediatr Diabetes | year= 2007 | volume= 8 Suppl 6 | issue=  | pages= 15-23 | pmid=17727381 | doi=10.1111/j.1399-5448.2007.00278.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17727381  }}</ref><ref>Type 1 Diabetes mellitus "Dennis Kasper, Anthony Fauci, Stephen Hauser, Dan Longo, J. Larry Jameson, Joseph Loscalzo"Harrison's Principles of Internal Medicine, 19e Accessed on December 27th,2016</ref><ref>{{Cite web|url=http://www.namrata.co/diabetes-mellitus-differential-diagnosis-and-management/|title=namrata|last=|first=|date=|website=|publisher=|access-date=}}</ref>
* [[DM1|Type1 DM]]
 
* [[Type 2 diabetes mellitus|Type 2 DM]]
* [[Maturity onset diabetes of the young|MODY-DM]]
* [[Psychogenic polydipsia]]
* [[Diabetes insipidus]]
* Transient hyperglycemia
* [[Steroid]] therapy
* [[Renal tubular acidosis|Renal tubular acidosis type-1]]
* [[Glucagonoma]]
* [[Cushing's syndrome]]
* [[Hypothyroidism]]
* [[Wolfram syndrome]]
* [[Alstrom syndrome]]
 
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Disease
! colspan="5" style="background:#4479BA; color: #FFFFFF;" align="center" |History and symptoms
! colspan="8" style="background:#4479BA; color: #FFFFFF;" align="center" |Laboratory findings
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Additional findings
|-
! style="background:#4479BA; color: #FFFFFF;" align="center" |Polyuria
! style="background:#4479BA; color: #FFFFFF;" align="center" |Polydipsia
! style="background:#4479BA; color: #FFFFFF;" align="center" |Polyphagia
! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss
! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight gain
! style="background:#4479BA; color: #FFFFFF;" align="center" |Serum glucose
! style="background:#4479BA; color: #FFFFFF;" align="center" |Urinary Glucose
! style="background:#4479BA; color: #FFFFFF;" align="center" |Urine PH
! style="background:#4479BA; color: #FFFFFF;" align="center" |Serum Sodium
! style="background:#4479BA; color: #FFFFFF;" align="center" |Urinary Glucose
! style="background:#4479BA; color: #FFFFFF;" align="center" |24 hrs cortisol level
! style="background:#4479BA; color: #FFFFFF;" align="center" |C-peptide level
! style="background:#4479BA; color: #FFFFFF;" align="center" |Serum glucagon
|-
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Diabetes mellitus type 1|Type 1 Diabetes mellitus]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''''↑'''''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N/'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↓'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Auto antibodies present ([[GAD65|Anti GAD-65]] and anti insulin anti bodies)
|-
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Diabetes mellitus type 2|Type 2 Diabetes mellitus]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Acanthosis nigricans]]
|-
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[MODY]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|-
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Psychogenic polydipsia]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↓'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|-
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Diabetes insipidus]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|-
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |Transient [[hyperglycemia]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N/'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |In hospitalized patients especially in [[ICU]] and [[CCU]]
|-
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Steroid]] therapy
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N/'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N/'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Acanthosis nigricans|Acanthosis nigricans,]]
|-
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[RTA|RTA 1]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hypokalemia]], [[nephrolithiasis]]
|-
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Glucagonoma]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Necrolytic migratory erythema]]
|-
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cushing's syndrome|Cushing syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |✔
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↓'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N/'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Moon face]], [[obesity]], [[buffalo hump]], easy [[Bruising|bruisibility]]
|}
|}


==References==
==References==
{{reflist|2}}
{{reflist|2}}
 
{{WH}}
[[Category:Types of cancer]]
{{WS}}
 
[[Category:Medicine]]
{{WikiDoc Help Menu}}
[[Category:Endocrinology]]
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Gastroenterology]]
[[Category:Surgery]]

Latest revision as of 22:39, 25 February 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2] Mohammed Abdelwahed M.D[3]

Overview

Glucagonoma must be differentiated from certain skin lesions in which necrolytic migratory erythema can be found such as acrodermatitis enteropathica, psoriasis, pellagra, and eczema. Glucagonoma should be differentiated from other causes of hyperglycemia include infection, diabetes mellitus, Cushing syndrome, renal failure, acute pancreatitis, severe stress, and prolonged fasting.

Differentiating Glucagonoma from other Diseases

Glucagonoma must be differentiated from certain skin lesions in which necrolytic migratory erythema can be found such as:[1]

Disease Clinical Picture Investigations Pictures
History Symptoms Signs
Glucagonoma[2][3][4][5] A family history of multiple endocrine neoplasia type 1
  • Serum glucagon
    • Increased plasma glucagon levels (>500 pg/mL)
    • Concentrations above 1000 pg/mL are diagnostic of glucagonoma
  • CT scan is used to determine:
    • The location of the tumor
    • Metastasis (usually liver metastasis)
      • Appear isodense with the liver on a non-contrasted study
Pemphigus foliaceus.[6][2][7][8] Autoimmune blistering disease of the skin with characteristic lesions that are scaly, crusted erosions, often on an erythematous base.[1]

Mucosal involvement is absent even with widespread disease

  • Cutaneous lesion that usually develops in a seborrheic distribution
  • The scalp, face, and trunk are common sites of involvement
  • Skin lesions may remain localized or may coalesce to cover large areas of skin
  • Pain or burning sensations frequently accompany the cutaneous lesions
  • Systemic symptoms are usually absent
  • The skin lesions usually consist of small, scattered superficial blisters
    • Lesions rapidly evolve into scaly, crusted erosions
    • Positive Nikolsky sign


Autoimmune IgG build up in the epidermis, then nearly almost all of the antibodies are aimed against desmoglein 1
Courtesy:http://www.atlasdermatologico.com.br/index.jsf
Pustular psoriasis[2][3]
Courtesy:http://www.atlasdermatologico.com.br/index.jsf
Acrodermatitis enteropathica[9][10][11]
  • Symptoms appear in infants after breast milk weaning
  • The appearance of erythematous patches and plaques of dry, scaly skin
  • Diarrhea
Courtesy:http://www.atlasdermatologico.com.br/index.jsf
Pellagra[12][13] Symmetric hyperpigmented rash, similar in color and distribution to a sunburn, which is present in the exposed areas of skin Niacin status can be assessed by measuring urinary N-methylnicotinamide or by measuring the erythrocyte NAD/NADP ratio 
Courtesy:http://www.atlasdermatologico.com.br/index.jsf
Chronic eczema (atopic dermatitis)
  • Symptoms beginning in a child before the age of 2 years or, in children <4 years
  • Dermatitis affecting the cheeks or dorsal aspect of extremities
  • Dry skin and severe pruritus that is associated with cutaneous hyperactivity to various environmental stimuli
  • Exposure to:
Courtesy:http://www.atlasdermatologico.com.br/index.jsf

Differentiating glucagonoma from other causes of hyperglycemia:

Glucagonoma can be differentiated from other causes of hyperglycemia which include:[14][15][16]

Disease History and symptoms Laboratory findings Additional findings
Polyuria Polydipsia Polyphagia Weight loss Weight gain Serum glucose Urinary Glucose Urine PH Serum Sodium Urinary Glucose 24 hrs cortisol level C-peptide level Serum glucagon
Type 1 Diabetes mellitus - Normal Normal N/ Normal Normal Auto antibodies present (Anti GAD-65 and anti insulin anti bodies)
Type 2 Diabetes mellitus - Normal Normal Normal Normal Acanthosis nigricans
MODY - Normal Normal Normal Normal N -
Psychogenic polydipsia - - - Normal Normal Normal Normal Normal Normal Normal -
Diabetes insipidus - - - Normal Normal Normal Normal Normal Normal Normal -
Transient hyperglycemia - - - - - Normal Normal Normal Normal N/ In hospitalized patients especially in ICU and CCU
Steroid therapy - - - Normal Normal N/ N/ Acanthosis nigricans,
RTA 1 - - - - Normal Normal Normal Normal Normal Normal Hypokalemia, nephrolithiasis
Glucagonoma - - - - - Normal Normal Normal - Normal Normal Necrolytic migratory erythema
Cushing syndrome - - - - - Normal N/ Normal Normal Moon face, obesity, buffalo hump, easy bruisibility

References

  1. Fang S, Li S, Cai T (2014). "Glucagonoma syndrome: a case report with focus on skin disorders". Onco Targets Ther. 7: 1449–53. doi:10.2147/OTT.S66285. PMC 4140234. PMID 25152626.
  2. Wilkinson DS (1973). "Necrolytic migratory erythema with carcinoma of the pancreas". Trans St Johns Hosp Dermatol Soc. 59 (2): 244–50. PMID 4793623.
  3. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV (1996). "The glucagonoma syndrome. Clinical and pathologic features in 21 patients". Medicine (Baltimore). 75 (2): 53–63. PMID 8606627.
  4. Zhang M, Xu X, Shen Y, Hu ZH, Wu LM, Zheng SS (2004). "Clinical experience in diagnosis and treatment of glucagonoma syndrome". HBPD INT. 3 (3): 473–5. PMID 15313692.
  5. Kindmark H, Sundin A, Granberg D, Dunder K, Skogseid B, Janson ET, Welin S, Oberg K, Eriksson B (2007). "Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years". Med. Oncol. 24 (3): 330–7. PMID 17873310.
  6. Bystryn JC, Rudolph JL (2005). "Pemphigus". Lancet. 366 (9479): 61–73. doi:10.1016/S0140-6736(05)66829-8. PMID 15993235.
  7. Chams-Davatchi C, Valikhani M, Daneshpazhooh M, Esmaili N, Balighi K, Hallaji Z; et al. (2005). "Pemphigus: analysis of 1209 cases". Int J Dermatol. 44 (6): 470–6. doi:10.1111/j.1365-4632.2004.02501.x. PMID 15941433.
  8. Martin LK, Werth VP, Villaneuva EV, Murrell DF (2011). "A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus". J Am Acad Dermatol. 64 (5): 903–8. doi:10.1016/j.jaad.2010.04.039. PMID 21353333.
  9. Prasad AS, Cossack ZT (1984). "Zinc supplementation and growth in sickle cell disease". Ann Intern Med. 100 (3): 367–71. PMID 6696358.
  10. Meftah S, Prasad AS, Lee DY, Brewer GJ (1991). "Ecto 5' nucleotidase (5'NT) as a sensitive indicator of human zinc deficiency". J Lab Clin Med. 118 (4): 309–16. PMID 1940572.
  11. Kiliç I, Ozalp I, Coŝkun T, Tokatli A, Emre S, Saldamli I; et al. (1998). "The effect of zinc-supplemented bread consumption on school children with asymptomatic zinc deficiency". J Pediatr Gastroenterol Nutr. 26 (2): 167–71. PMID 9481631.
  12. Prousky JE (2003). "Pellagra may be a rare secondary complication of anorexia nervosa: a systematic review of the literature". Altern Med Rev. 8 (2): 180–5. PMID 12777163.
  13. Wan P, Moat S, Anstey A (2011). "Pellagra: a review with emphasis on photosensitivity". Br J Dermatol. 164 (6): 1188–200. doi:10.1111/j.1365-2133.2010.10163.x. PMID 21128910.
  14. Barrett TG (2007). "Differential diagnosis of type 1 diabetes: which genetic syndromes need to be considered?". Pediatr Diabetes. 8 Suppl 6: 15–23. doi:10.1111/j.1399-5448.2007.00278.x. PMID 17727381.
  15. Type 1 Diabetes mellitus "Dennis Kasper, Anthony Fauci, Stephen Hauser, Dan Longo, J. Larry Jameson, Joseph Loscalzo"Harrison's Principles of Internal Medicine, 19e Accessed on December 27th,2016
  16. "namrata".

Template:WH Template:WS